Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of a trivalent influenza subunit vaccine in people aged 3 years and older
CTR20263948Phase 3Active
- Sponsor
- Beijing Baihui Biotechnology
- Start
- Oct 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trivalent subunit influenza vaccine in influenza, sponsored by Beijing Baihui Biotechnology. Started Oct 2026; status: active.
02
Drugs
trivalent subunit influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20263948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263948.